The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Gilligan James P since 2005.
The trader's CIK number is 1192945.
At the time of the last reporting, Gilligan James P was the Director of Unigene Laboratories Inc. (stock ticker symbol UGNE).
Also see all insider trading activities at Unigene Laboratories Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2008 | HBRM | 605,769 | $7,874 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2009 | UGNE | 0 | $0 | 75,000 | $87,050 | 115,000 | $72,450 |
| 2007 | UGNE | 600 | $1,440 | 0 | $0 | 0 | $0 |
| 2005 | UGNE | 0 | $0 | 20,000 | $90,000 | 20,000 | $39,380 |
| 2005 | UGNE | 0 | $0 | 100,000 | $405,197 | 160,000 | $329,005 |
2. Unigene Laboratories Inc (UGNE)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2008-10-06 | HBRM | Buy | 605,769 | .01 | 7,874 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2009-11-03 | UGNE | Option Ex | 115,000 | .63 | 72,450 |
| 2009-11-03 | UGNE | Sale | 10,000 | 1.23 | 12,300 |
| 2009-11-04 | UGNE | Sale | 65,000 | 1.15 | 74,750 |
| 2007-05-23 | UGNE | Buy | 600 | 2.40 | 1,440 |
| 2005-12-21 | UGNE | Option Ex | 20,000 | 1.97 | 39,380 |
| 2005-12-21 | UGNE | Sale | 20,000 | 4.50 | 90,000 |
| 2005-12-07 | UGNE | Option Ex | 63,500 | 2.81 | 178,562 |
| 2005-12-08 | UGNE | Option Ex | 96,500 | 1.56 | 150,443 |
| 2005-12-07 | UGNE | Sale | 63,500 | 4.01 | 254,635 |
| 2005-12-08 | UGNE | Sale | 36,500 | 4.12 | 150,562 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Gilligan James P (Director of Unigene Laboratories Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.